Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

In a world where respiratory issues are increasingly common, finding practical solutions can be daunting. Breathe Drops ...

COPD-asthma-devices-market2025 PORTLAND, DE, UNITED STATES, January 29, 2025 /EINPresswire / -- Day-to-day exposure to environmental pollutio ...

New York, USA, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...

A small proportion of veterans who went from a metered-dose inhaler to a dry-powder inhaler had to revert to the metered-dose ...

For surgeons already split on their preference of inhaled pulmonary vasodilator to prevent postoperative right ventricular ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

Background Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic obstructive pulmonary disease (COPD) is debated. Objectives To establish, ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

When we think of artificial intelligence (AI), data science and the potential real-world impact of these rapidly developing fields, we tend to look to the future—particularly when it comes to ...

Treasury Secretary Janet Yellen was asked if she has ever “inhaled” marijuana, and she confirmed that she did at one point. Yellen appeared on “The Late Show with Stephen Colbert” on ...